Zacks: Brokerages Anticipate Genomic Health, Inc. (GHDX) to Post $0.31 Earnings Per Share
Equities research analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to post earnings per share (EPS) of $0.31 for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Genomic Health’s earnings. The lowest EPS estimate is $0.30 and the highest is $0.33. Genomic Health reported earnings per share of $0.08 in the same quarter last year, which suggests a positive year over year growth rate of 287.5%. The firm is expected to announce its next earnings results on Thursday, March 14th.
On average, analysts expect that Genomic Health will report full-year earnings of $1.06 per share for the current financial year, with EPS estimates ranging from $1.04 to $1.07. For the next year, analysts expect that the firm will post earnings of $1.23 per share, with EPS estimates ranging from $1.04 to $1.55. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Genomic Health.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million during the quarter, compared to the consensus estimate of $94.27 million. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.06) earnings per share.
In other news, Director Bros. Advisors Lp Baker sold 204,300 shares of the business’s stock in a transaction dated Tuesday, November 13th. The stock was sold at an average price of $79.33, for a total transaction of $16,207,119.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kimberly J. Popovits sold 50,000 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $65.28, for a total value of $3,264,000.00. The disclosure for this sale can be found here. Insiders have sold 545,394 shares of company stock worth $42,271,195 in the last 90 days. Insiders own 45.80% of the company’s stock.
Several hedge funds have recently modified their holdings of GHDX. Globeflex Capital L P purchased a new stake in shares of Genomic Health during the second quarter worth about $116,000. Sun Life Financial INC acquired a new stake in shares of Genomic Health during the second quarter worth about $122,000. SG Americas Securities LLC acquired a new stake in shares of Genomic Health during the second quarter worth about $162,000. Pacer Advisors Inc. acquired a new stake in shares of Genomic Health during the third quarter worth about $171,000. Finally, Trexquant Investment LP acquired a new stake in shares of Genomic Health during the third quarter worth about $202,000. Institutional investors and hedge funds own 90.84% of the company’s stock.
GHDX stock opened at $75.76 on Monday. The stock has a market capitalization of $2.85 billion, a P/E ratio of 7,576.00 and a beta of 0.44. Genomic Health has a 1-year low of $26.54 and a 1-year high of $92.18.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Featured Article: Marijuana Stocks Future Looks Bright
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.